Hims & Hers Health, Inc. (NYSE:HIMS) Insider Irene Becklund Sells 2,203 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Irene Becklund sold 2,203 shares of the firm’s stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $28.78, for a total value of $63,402.34. Following the transaction, the insider now owns 8,007 shares in the company, valued at approximately $230,441.46. This represents a 21.58 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Hims & Hers Health Stock Down 7.4 %

Shares of Hims & Hers Health stock opened at $25.93 on Friday. The firm has a market capitalization of $5.76 billion, a P/E ratio of 58.93 and a beta of 1.37. Hims & Hers Health, Inc. has a 52 week low of $11.20 and a 52 week high of $72.98. The company has a 50 day moving average price of $39.82 and a 200 day moving average price of $29.84.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. As a group, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HIMS has been the topic of a number of research reports. Leerink Partners raised their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research report on Tuesday, February 25th. Canaccord Genuity Group upped their target price on Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. Piper Sandler lifted their price target on Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a report on Tuesday, February 25th. BTIG Research initiated coverage on Hims & Hers Health in a research note on Tuesday, January 7th. They set a “buy” rating and a $35.00 price objective for the company. Finally, Truist Financial lifted their target price on Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a research note on Wednesday, February 26th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $37.31.

Institutional Trading of Hims & Hers Health

Several large investors have recently added to or reduced their stakes in the company. Crewe Advisors LLC acquired a new stake in shares of Hims & Hers Health during the fourth quarter worth about $28,000. Raleigh Capital Management Inc. lifted its stake in Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares during the period. Blume Capital Management Inc. boosted its holdings in shares of Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 600 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in shares of Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after acquiring an additional 1,413 shares during the period. Finally, Summit Securities Group LLC purchased a new position in shares of Hims & Hers Health during the fourth quarter worth $38,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.